A Placebo-controlled Study to Determine the Efficacy and Safety of 300 and 450 µg/Day Transdermal Testosterone in Female Patients With Low Ejection Fraction and Symptomatic Heart Failure.

Trial Profile

A Placebo-controlled Study to Determine the Efficacy and Safety of 300 and 450 µg/Day Transdermal Testosterone in Female Patients With Low Ejection Fraction and Symptomatic Heart Failure.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2012

At a glance

  • Drugs Testosterone (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms CORDELIA
  • Sponsors Procter & Gamble; Warner Chilcott
  • Most Recent Events

    • 26 May 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
    • 26 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 26 May 2010 Planned end date changed from 1 Dec 2010 to 1 May 2010 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top